Abstract:188 Background: Cancer cachexia leads to reduced overall survival (OS) in mCRC. Novel therapeutics targeting the myostatin/activin pathway can reverse cachexia. Here we investigate the effect of myostatin/activin pathway gene expression and SNPs in mCRC patients (pts). Methods: Blood samples from 836 pts enrolled in 3 randomized first-line trials: TRIBE (FOLFIRI bevacizumab [bev]; FOLFOXIRI bev), FIRE-3 (FOLFIRI bev; FOLFIRI cetuximab [cet]) and MAVERICC (FOLFIRI bev; FOLFOX bev) were genotyped by Illumina OncoArray. The impact on outcome of 13 SNPs from 5 myostatin/activin genes ( ACVR1B, ACVR2A, ACVR2B, MSTN, INHBA) was tested. Gene expression analysis included 433 mCRC pts treated with either bev (n = 226) or cet (n = 207) in combination with first-line chemotherapy from the CALGB/SWOG 80405 trial (NCT00265850). RNA isolated from FFPE tumor samples were sequenced with HiSeq 2500 (Illumina). OS and progression-free survival (PFS) were compared by gene expression tertiles: low (L), medium (M), and high (H). Logrank test was used for univariate (UV) analysis, Cox proportional hazards regression for multivariate (MV). Results: Pts with the germline G/G variant of ACVR2B rs2276541 had worse PFS (FIRE-3 bev: 9.7 vs 12.2 months [mo]; UV P = .044, MV P = .027; HR 2.10, 95%CI 1.13 - 3.38 & FIRE-3 cet: 7.6 vs 13.2 mo; UV P = .047; HR 1.65, 95%CI 1.00 - 2.72) and tumor response (TRIBE FOLFIRI bev: 48 vs 61%, MV P = .035) compared to any A carriers. Rs3749387 C/C variant in the same gene showed longer OS (MAVERICC FOLFOX bev: 36.9 vs 24.3 mo; MV P = .005; HR = 0.41, 95%CI 0.21-0.80) and PFS (MAVERICC FOLFIRI bev: 14.5 vs 11.8 mo; MV P = .009; HR = 0.53, 95%CI 0.32-0.88) relative to G variants. Any C allele in ACVR2A rs10497025 demonstrated improved OS (MAVERICC FOLFOX bev: 25.5 vs 11.9 mo; HR = 2.38, UV P = .035; 95%CI 1.03- 5.50 & TRIBE FOLFIRI bev: 26.9 vs 22.4 mo; UV P = .017; HR = 1.90, 95%CI 1.11-3.26) and PFS (FIRE-3 - FOLFIRI cet : 32.1 vs 12.2 mo; UV P = .047; HR = 0.47, 95%CI 0.22-1.02 & MAVERICC FOLFOX bev 11.0 vs 6.8 mo; UV P = .006; HR = 2.52, 95%CI 1.26-5.00) relative to G/G. Tumor ACVR1B-H expression was associated with longer PFS (L/M/H, 9.5 vs 10.9 vs 13.5 mo, UV P = .034) and OS (L/M/H, 25.0 vs 28.2 vs 38.6 mo, UV P < .001) in all treated pts. ACVR1B-H also conferred improved OS in treatment subgroups (L/M/H; cet: 21.0 vs 27.4 vs 40.3 mo, UV P < .001; bev: 25.9 vs 29.0 vs 36.9 mo, UV P = .025). ACVR2B-L correlated with worse PFS (L/M/H, 10.3 vs 12.2 vs 11.2 mo, UV P = .043) and OS (L/M/H, 24.7 vs 33.8 vs 34.9 mo; P = .006) in the overall cohort. This association held true in cet treated patients (OS 21.2 vs 35.8 vs 37.1 mo; UV P < .001) but not bev. Conclusions: Our results suggest a role of cachexia SNPs and gene expression as a prognostic marker for mCRC undergoing first line treatment. These biomarkers may enable targeted treatments for cancer cachexia and support exploring this approach in combination with standard therapy in selected pts.

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

Associations Between Novel Genetic Variants in the Promoter Region of MALAT1 and Risk of Colorectal Cancer

Identification of Potential Functional Variants and Genes at 18q21.1 Associated with the Carcinogenesis of Colorectal Cancer.

Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC).

Genetic Polymorphism in a VEGF-Independent Angiogenesis Gene ANGPT1 and Overall Survival of Colorectal Cancer Patients after Surgical Resection

Genetic Variation Determines VEGF-A Plasma Levels in Cancer Patients

Abstract A035: Protein quantitative trait loci analysis in diverse prostate cancer patients: A focus on angiogenesis

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).

Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in patients (pts) with metastatic colorectal cancer (mCRC).

Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome

Proteogenomic Characterization and Comprehensive Integrative Genomic Analysis of Human Colorectal Cancer Liver Metastasis

ANGPTL2+cancer-associated fibroblasts and SPP1+macrophages are metastasis accelerators of colorectal cancer

Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer

Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).

166 Common Genetic Variation and Survival After Colorectal Cancer Diagnosis: A Genome-Wide Analysis of Six Studies

A Genome-Wide Association Study (gwas) of Overall Survival (os) in 609 Metastatic Colorectal Cancer (mcrc) Patients Treated with Chemotherapy and Biologics in Calgb 80405

Identification of Key Genes in the Colorectal Cancer Immune Microenvironment Through Integrated Analysis of Immune Infiltration Algorithms and Single-Cell Transcriptomics

Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).

Navigating colorectal cancer prognosis: A Treg‐related signature discovered through single‐cell and bulk transcriptomic approaches

Targeted Re-Sequencing Identified Rs3106189 At The 5 ' Utr Of Tapbp And Rs1052918 At The 3 ' Utr Of Tcf3 To Be Associated With The Overall Survival Of Colorectal Cancer Patients

Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets